Turning Digital MedTech Litigation Risk into Ecosystem Advantage
Digitalization is turning biotech products into connected MedTech ecosystems where data, software and devices interact across hospitals and patients’ homes. This boosts clinical value but exposes companies to new IP risks, especially from non-practicing entities targeting software, connectivity and data features. The case shows how a diagnostics firm uses layered IP – patents, trade secrets, design and data rights plus contracts – to secure its platform. Continuous FTO, defensive publishing, robust internal processes and focused use of AI in IP analytics help anticipate and manage litigation. Done well, IP risk management👉 Process of identifying, assessing, and controlling threats to assets and objectives. becomes a strategic advantage for sustainable digital health business models.
Background material on the IPBA Connect platform
Here 🧭diplex pages by IP subject matter experts:
- IP protection in the life sciences by Christian Heubeck
- Operational IP Management for Industrial Practice by Per Wendin
- IP Process Management by Max Feucker
- IP Essentials for Founders in Digital Health and Life Sciences by Maria Boicova-Wynants
Here the relevant 🔎IP Management👉 Strategic and operative handling of IP to maximize value. Glossary entries on:
Digital life sciences and MedTech: from products to data ecosystems
Life sciences used to be about physical things: reagents in a vial, instruments in a lab, implants in a body. Today, the most valuable part of many life sciences offerings is the invisible layer of data, algorithms and connectivity wrapped around those physical products. Diagnostic tests are linked to cloud platforms, treatment decisions are guided by analytics dashboards, and patient journeys continue at home via connected devices and apps. The result is a converging landscape where biotechnology and MedTech increasingly look like one integrated digital health ecosystem.
In that ecosystem, success is no longer defined only by clinical performance. It depends on how seamlessly devices, assays, software and data services interact across institutional boundaries. This makes digital life sciences and MedTech incredibly powerful, but it also exposes companies to new categories of intellectual property👉 Creations of the mind protected by legal rights. risk👉 The probability of adverse outcomes due to uncertainty in future events.. Software code, communication standards, AI models and user interfaces sit on top of classical biotech inventions👉 A novel method, process or product that is original and useful. and become attractive targets for litigation.
Case study: a digital diagnostics platform as ecosystem anchor
The presentation uses a typical mid-sized European diagnostics company as a case study. The company began in the early 2000s as a specialist in molecular assays for infectious diseases. Its original success mechanism was straightforward: develop highly reliable reagents and instruments, prove clinical performance in hospitals, secure regulatory approval and win tenders for lab equipment.
Around a decade later, the company realised that hospitals and laboratories were under pressure to integrate diagnostics data into hospital information systems and national e‑health platforms. It started to add connectivity modules to its instruments, offered secure cloud storage for test results and developed a web-based dashboard for clinicians. Over time, this evolved into a full digital diagnostics platform with APIs for third-party MedTech devices, interfaces for electronic health records and a patient app for remote monitoring.
The company’s history illustrates how a traditional biotech business becomes an ecosystem player. Its mechanisms for success shifted from isolated product excellence to orchestrating a network of devices, data flows and user roles. Revenue increasingly came from recurring platform fees, analytics packages and co-created digital services with hospital partners, not only from selling cartridges and instruments.
Mechanisms of success in a connected MedTech ecosystem
Several mechanisms underpin the success of such a digital diagnostics platform. First, there is technical integration: the platform connects assay instruments, bedside devices, hospital IT systems and sometimes wearable sensors. Second, there is data network effect: the more sites connect and the more patients are monitored, the more robust the analytics models become, which improves clinical decision support and makes the platform more attractive. Third, there is regulatory and trust capital. By owning the full pathway from data acquisition to analytics and reporting, the company can implement robust quality, security and compliance frameworks. Hospitals and regulators prefer a provider that can take system-wide responsibility instead of a patchwork of loosely connected vendors. Fourth, there is business model👉 A business model outlines how a company creates, delivers, and captures value. innovation👉 Practical application of new ideas to create value.. Instead of one-off sales, long-term contracts and value-based pricing models become possible, tying the success of the platform to clinical outcomes and operational efficiency.
All of these mechanisms depend on the ability to invest in innovation and to keep opportunistic imitators from simply cloning key digital components. This is where the IP strategy👉 Approach to manage, protect, and leverage IP assets. becomes central to making the ecosystem possible, sustainable and profitable.
IP strategy as backbone of a sustainable MedTech ecosystem
In the case study, the company’s IP strategy evolved from classic biotechnology protection to a layered approach covering the entire digital ecosystem. Foundational patents secure the unique assay chemistry, sensor designs and instrument architecture. On top of that, a second patent👉 A legal right granting exclusive control over an invention for a limited time. layer protects connectivity modules, data processing pipelines and specific analytics methods that translate raw signals into clinically actionable insights.
Trade secrets play a complementary role. The company keeps its AI model architectures, training data curation methods and certain performance-optimisation tricks confidential. This is particularly important where patenting would require disclosing details that competitors could easily adapt. Know‑how and process documentation inside the organisation ensure that these trade secrets can be defended in court if misappropriation occurs.
The third layer concerns rights in software, databases and user interfaces. Copyright👉 A legal protection for original works, granting creators exclusive rights. protects specific implementations of software modules. Design rights cover visual elements of dashboards and device interfaces, preventing copycat products from simply adopting the same look and feel. Database rights and carefully crafted terms of use protect the aggregated clinical datasets and derived insights that are central to the platform’s value.
Finally, contracts and licensing👉 Permission to use a right or asset granted by its owner. frameworks complete the IP strategy. API terms, data processing agreements and platform participation contracts clearly allocate ownership and usage rights between hospitals, technology partners and the platform provider. This combination of patents, secrets, designs, copyright and contracts is what makes the ecosystem sustainable and profitable: partners can contribute their own IP, innovate on top of the platform and still trust that the core provider can keep investing in long-term infrastructure.
How biotechnology products are becoming digital MedTech solutions
Question 1 in the case asks how biotechnology products are increasingly turning into digital products and how the industry border to MedTech is disappearing. The case study company illustrates this shift clearly. A diagnostic assay that once ended at the lab bench now continues as data flows through connectivity modules into a hospital IT system, is aggregated in the cloud, analysed by AI and visualised on clinicians’ tablets.
Biotech products integrate sensors that measure multiple biomarkers simultaneously, generating continuous data streams rather than single end points. MedTech elements such as smart pumps, implantable devices or wearables provide the hardware interface to patients. Software then binds everything together, translating complex biological signals into simple alerts, risk scores or treatment recommendations. From the user’s perspective, the distinction between a “biotech product” and a “MedTech device” fades; they experience a connected digital care solution.
Regulatory frameworks also push this convergence. Combination products, software as a medical device👉 Software intended for medical purposes that functions without a hardware device. and digital therapeutics blur classification categories. Clinical value increasingly depends on how well biological measurement, device integration and digital decision support work together. As a result, innovation projects typically involve mixed teams from biotech, MedTech and software engineering rather than clearly separated silos.
Why NPE litigation is rising in digital life sciences and MedTech
Question 2 addresses the new litigation threats by non-practicing entities (NPEs) and the anti-litigation strategies used by IP departments. NPEs are particularly attracted to digital life sciences and MedTech for several reasons. First, these markets use many general-purpose digital technologies—wireless communication, cloud architectures, data compression, user interface patterns—that have been heavily patented, often by entities outside the healthcare sector.
Second, the economic value per device or per patient can be very high. A patented feature embedded in a diagnostic platform used across thousands of hospitals and millions of patients represents a substantial revenue base. This makes even narrow patents an attractive assert target. Third, the system complexity gives NPEs leverage. It is relatively easy to allege that some internal data processing step, connectivity feature or interface behaviour falls within the scope of an acquired patent portfolio, while it is difficult and costly for the operating company to prove otherwise.
Industry surveys show that a majority of companies in this space are reacting. Close to 60% optimise their defence strategies against NPEs and more than half intensify licensing and cooperation activities. A significant share already uses AI tools in litigation defence, and many more plan to introduce them soon. These numbers underline that NPE litigation is no longer a rare exception but a strategic risk for IP departments in digital life sciences.
IP department playbook against NPE patent threats
In the case study, the IP department builds a multi-layered defence to handle NPE threats. The starting point is systematic patent landscaping in the technology domains used by the platform—connectivity standards, cloud infrastructure, security protocols, data analytics and user interfaces. This enables early identification of high‑risk patent owners and NPE aggregators.
Freedom-to-operate analyses are no longer one‑off exercises before launch but continuous monitoring activities as the platform evolves. The IP team uses technical mapping to understand which modules would be impacted by an assertion and how easily those modules could be redesigned. Where exposure is high, the company proactively seeks licences or participates in patent pools and standard-setting organisations to secure more favourable terms.
Defensive publishing and selective patenting complement this defensive posture. By publishing certain technical solutions, the company reduces the available white space for NPEs to patent around its architecture. At the same time, it builds its own portfolio in cross‑licensable fields, giving it bargaining chips in negotiations and settlements. Litigation funding, insurance and scenario planning ensure that the company can financially withstand and strategically manage cases that still emerge.
Designing internal processes to avoid and prepare for litigation
Question 3 in the case asks for company-internal processes to avoid or prepare for litigation. The presentation highlights that litigation resilience is not a last-minute legal activity but the outcome of daily practices across R&D, product management, IT and business development.
First, there is a structured innovation process👉 A structured journey of creating and implementing new ideas. where IP checks are integrated into each development stage. Concept gates include high-level landscape scans; design stages require more detailed FTO assessments; release gates verify that any known third-party IP exposure is either addressed by design-around solutions or backed by licences. This prevents surprises after market launch.
Second, documentation and traceability are treated as strategic assets. Design decisions, alternative concepts, sources of inspiration and internal knowledge creation are properly recorded. This evidence can later demonstrate independent development in court, which is particularly important when facing allegations from NPEs or competitors who claim that features were copied.
Third, contracts and procurement processes are aligned with IP risk management. Supplier agreements include clear warranties and indemnification clauses for third-party IP rights. Collaboration contracts define ownership and usage rights for jointly developed modules. Open-source software👉 Freely accessible code that can be used, modified, and shared. policies ensure that third-party components are vetted for licence compatibility and security before integration into regulated products.
Finally, the company invests in education. Engineers, product managers, clinical specialists and sales teams receive concise training on practical IP risk topics: recognising warning signs in customer discussions, avoiding problematic statements in marketing materials, handling confidential information correctly and following escalation paths when potential infringement👉 Unauthorized use or exploitation of IP rights. is suspected.
The role of AI in IP risk management and litigation preparedness
The case then discusses the role of AI technology in those processes. AI is already used by many companies for prior-art searches, claim charting, clustering of litigation cases and predicting the behaviour of specific courts or judges. In digital life sciences and MedTech, AI also helps map complex system architectures to large patent portfolios, highlighting hot spots where many claims overlap with a single module or interface.
However, using AI does not remove the need for good processes; it changes what good processes look like. Data quality management👉 a systematic way to ensure products and services meet customer expectations and standards. becomes critical: training and evaluation sets for AI tools must be curated to avoid blind spots in important technology fields or jurisdictions. Transparency and explainability matter, because executives and engineers must understand why an AI tool flags a certain patent as high-risk or recommends a particular design-around strategy.
Human oversight remains non-negotiable. The company sets up multidisciplinary review boards where IP experts, engineers and regulatory specialists challenge AI outputs before decisions are made. Clear audit trails document which information was used when making strategic choices, so that the company can later show that it acted with due care. Where AI systems are used to support litigation, legal teams ensure that privileged information is handled appropriately and that external tools comply with confidentiality obligations.
In practice, this means that IP processes are redesigned to treat AI as a collaborator, not as an oracle. Standard operating procedures define when AI analysis is mandatory, how confidence scores are interpreted and how conflicting insights from human experts and AI are resolved. This structured integration reduces noise, speeds up routine tasks and frees human experts to focus on the complex strategic questions that machines cannot answer.
From litigation risk to strategic advantage in digital MedTech
The overall message of the case is that digitalization does not only create new litigation risks; it also creates an opportunity to build stronger, more resilient IP strategies. By understanding how biotech products transform into digital MedTech ecosystems, companies can design IP portfolios that secure their role as orchestrators rather than commodity suppliers.
A thoughtful combination of patents, trade secrets, design rights, contracts and data governance enables the creation of platforms where partners can innovate together while respecting each other’s contributions. At the same time, robust internal processes and smart use of AI make it possible to anticipate and navigate NPE threats instead of reacting in panic when lawsuits arrive.
For life sciences and MedTech companies, the question is therefore not whether digitalization will increase IP litigation risk, but whether they will be prepared. Those that treat IP and litigation preparedness as integral parts of their digital strategy can turn the pressure from NPEs and competitors into a catalyst for better governance, deeper partnerships and more sustainable business models.
